Prelude Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $268K | Buy |
30,331
+7,253
| +31% | +$64.2K | 0.03% | 656 |
|
|
2025
Q1 | $181K | Buy |
23,078
+140
| +0.6% | +$1.1K | 0.01% | 878 |
|
|
2024
Q4 | $241K | Buy |
22,938
+11,215
| +96% | +$118K | 0.02% | 781 |
|
|
2024
Q3 | $154K | Sell |
11,723
-60,271
| -84% | -$790K | 0.01% | 998 |
|
|
2024
Q2 | $1.01M | Buy |
+71,994
| New | +$1.01M | 0.07% | 277 |
|
|
2024
Q1 | – | Sell |
-12,076
| Closed | -$171K | – | 1202 |
|
|
2023
Q4 | $171K | Buy |
+12,076
| New | +$171K | 0.01% | 848 |
|
|
2021
Q1 | – | Sell |
-51,118
| Closed | -$341K | – | 1092 |
|
|
2020
Q4 | $341K | Buy |
+51,118
| New | +$341K | 0.01% | 473 |
|
|
2020
Q3 | – | Sell |
-20,815
| Closed | -$168K | – | 1368 |
|
|
2020
Q2 | $168K | Buy |
+20,815
| New | +$168K | 0.01% | 535 |
|
|
2017
Q4 | – | Sell |
-6,900
| Closed | -$72K | – | 1219 |
|
|
2017
Q3 | $72K | Buy |
6,900
+2,900
| +73% | +$30.3K | 0.01% | 902 |
|
|
2017
Q2 | $44K | Buy |
4,000
+1,400
| +54% | +$15.4K | ﹤0.01% | 939 |
|
|
2017
Q1 | $25K | Buy |
2,600
+2,500
| +2,500% | +$24K | ﹤0.01% | 1172 |
|
|
2016
Q4 | $1K | Sell |
100
-24,686
| -100% | -$247K | ﹤0.01% | 1447 |
|
|
2016
Q3 | $307K | Buy |
+24,786
| New | +$307K | 0.03% | 379 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 1845 |
|
|
2014
Q4 | – | Hold |
0
| – | – | – | 1786 |
|
|
2014
Q2 | – | Sell |
-11,210
| Closed | -$150K | – | 1719 |
|
|
2014
Q1 | $150K | Buy |
+11,210
| New | +$150K | 0.02% | 734 |
|